MX2016015389A - Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. - Google Patents
Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.Info
- Publication number
- MX2016015389A MX2016015389A MX2016015389A MX2016015389A MX2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- cynomolgus
- antibody
- epsilon
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170140 | 2014-05-28 | ||
| EP14180572 | 2014-08-11 | ||
| PCT/EP2015/061457 WO2015181098A1 (en) | 2014-05-28 | 2015-05-22 | Antibodies binding to human and cynomolgus cd3 epsilon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016015389A true MX2016015389A (es) | 2017-04-13 |
Family
ID=53268799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016015389A MX2016015389A (es) | 2014-05-28 | 2015-05-22 | Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170233475A1 (enExample) |
| EP (2) | EP3763739A1 (enExample) |
| JP (1) | JP6738285B2 (enExample) |
| KR (1) | KR20170003591A (enExample) |
| CN (1) | CN106459201A (enExample) |
| AU (1) | AU2015266077A1 (enExample) |
| BR (1) | BR112016022819A2 (enExample) |
| CA (1) | CA2942453A1 (enExample) |
| IL (1) | IL247740A0 (enExample) |
| MX (1) | MX2016015389A (enExample) |
| RU (1) | RU2016151235A (enExample) |
| SG (1) | SG11201609950YA (enExample) |
| WO (1) | WO2015181098A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2901794T3 (es) | 2015-12-09 | 2022-03-23 | Hoffmann La Roche | Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco |
| WO2017150762A1 (ko) * | 2016-02-29 | 2017-09-08 | (주)메디톡스 | 항-CD3γε 항체 및 이의 용도 |
| CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| FI3561057T3 (fi) * | 2016-12-22 | 2025-10-07 | Daiichi Sankyo Co Ltd | Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| EP3634998B8 (en) * | 2017-06-05 | 2025-04-09 | Numab Therapeutics AG | Anti-cd3 epsilon antibodies |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| TWI820041B (zh) * | 2017-09-21 | 2023-11-01 | 中國大陸商上海藥明生物技術有限公司 | 新型抗CD3ε抗體 |
| US12486325B2 (en) | 2017-09-21 | 2025-12-02 | WuXi Biologics Ireland Limited | Anti-CD3epsilon antibodies |
| WO2019105864A1 (en) | 2017-11-30 | 2019-06-06 | F. Hoffmann-La Roche Ag | B-cell cultivation method |
| CA3093330A1 (en) * | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
| MX420253B (es) * | 2018-05-24 | 2025-02-10 | Janssen Biotech Inc | Anticuerpos anti-cd3 y usos de estos. |
| WO2019244107A1 (en) * | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
| IL298444A (en) * | 2020-05-27 | 2023-01-01 | Janssen Biotech Inc | Proteins containing cd3 antigen binding sites and uses thereof |
| JP2023542209A (ja) * | 2020-09-24 | 2023-10-05 | モルフォシス・アーゲー | ヒトｃｄ３イプシロンに結合する新規なヒト抗体 |
| CN114656562B (zh) | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| EP4314075A4 (en) * | 2021-03-24 | 2025-04-09 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CD3 |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| EP4329800A1 (en) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| CN115536740A (zh) * | 2021-06-30 | 2022-12-30 | 苏州方德门达新药开发有限公司 | 介导细胞内有效滞留cd3的空间构象表位及其应用 |
| CN113755435B (zh) * | 2021-10-15 | 2023-10-13 | 苏州药明康德新药开发有限公司 | 一种食蟹猴pbmc分离方法 |
| US20230295310A1 (en) * | 2022-03-20 | 2023-09-21 | Abcellera Biologics Inc. | CD3 T-Cell Engagers and Methods of Use |
| KR20240158351A (ko) * | 2022-03-22 | 2024-11-04 | 모르포시스 아게 | Cd3에 특이적인 탈면역화 항체 |
| MX2024011468A (es) | 2022-03-23 | 2024-09-25 | Hoffmann La Roche | Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia. |
| AU2023251832A1 (en) | 2022-04-13 | 2024-10-17 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD272473B3 (de) * | 1988-06-13 | 1993-01-21 | Univ Leipzig | Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten |
| JPH0630786A (ja) * | 1992-07-14 | 1994-02-08 | Kyowa Hakko Kogyo Co Ltd | バイスペシフィック抗体 |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| EP1940881B1 (en) * | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| DK2155788T3 (da) * | 2007-04-03 | 2012-10-08 | Amgen Res Munich Gmbh | Krydsartsspecifikke bispecifikke bindemidler |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| CN107827985A (zh) * | 2011-05-21 | 2018-03-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| US20170073415A1 (en) * | 2014-05-12 | 2017-03-16 | Numab Ag | Novel multispecific molecules and novel treatment methods based on such multispecific molecules |
-
2015
- 2015-05-22 JP JP2016569639A patent/JP6738285B2/ja not_active Expired - Fee Related
- 2015-05-22 KR KR1020167033022A patent/KR20170003591A/ko not_active Withdrawn
- 2015-05-22 CA CA2942453A patent/CA2942453A1/en not_active Abandoned
- 2015-05-22 BR BR112016022819A patent/BR112016022819A2/pt not_active Application Discontinuation
- 2015-05-22 MX MX2016015389A patent/MX2016015389A/es unknown
- 2015-05-22 SG SG11201609950YA patent/SG11201609950YA/en unknown
- 2015-05-22 EP EP20163877.2A patent/EP3763739A1/en not_active Withdrawn
- 2015-05-22 CN CN201580026998.5A patent/CN106459201A/zh active Pending
- 2015-05-22 WO PCT/EP2015/061457 patent/WO2015181098A1/en not_active Ceased
- 2015-05-22 EP EP15725002.8A patent/EP3149041A1/en not_active Ceased
- 2015-05-22 AU AU2015266077A patent/AU2015266077A1/en not_active Abandoned
- 2015-05-22 RU RU2016151235A patent/RU2016151235A/ru not_active Application Discontinuation
-
2016
- 2016-09-11 IL IL247740A patent/IL247740A0/en unknown
- 2016-11-22 US US15/359,199 patent/US20170233475A1/en not_active Abandoned
-
2020
- 2020-01-23 US US16/751,062 patent/US20200299385A1/en not_active Abandoned
- 2020-01-23 US US16/751,046 patent/US20200325224A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016151235A3 (enExample) | 2019-01-18 |
| RU2016151235A (ru) | 2018-06-28 |
| US20200299385A1 (en) | 2020-09-24 |
| US20200325224A1 (en) | 2020-10-15 |
| KR20170003591A (ko) | 2017-01-09 |
| CA2942453A1 (en) | 2015-12-03 |
| JP6738285B2 (ja) | 2020-08-12 |
| CN106459201A (zh) | 2017-02-22 |
| AU2015266077A1 (en) | 2016-09-29 |
| SG11201609950YA (en) | 2016-12-29 |
| IL247740A0 (en) | 2016-11-30 |
| BR112016022819A2 (pt) | 2018-01-16 |
| EP3763739A1 (en) | 2021-01-13 |
| JP2017516786A (ja) | 2017-06-22 |
| US20170233475A1 (en) | 2017-08-17 |
| EP3149041A1 (en) | 2017-04-05 |
| WO2015181098A1 (en) | 2015-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016015389A (es) | Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
| MX2020003046A (es) | Anticuerpos anti-hla-a2 y metodos para utilizar los mismos. | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| PH12021550041A1 (en) | Anti-sortilin antibodies and methods of use thereof | |
| WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| NZ603226A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| MX2022007774A (es) | Anticuerpos de union a abril modificados. | |
| NZ607969A (en) | Cd33 binding agents | |
| AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
| MX341958B (es) | Anticuerpos contra el il33r humano y usos de los mismos. | |
| MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
| WO2015173756A3 (en) | Bispecific antibodies with engineered ch1-cl interfaces | |
| SG10201803473WA (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide | |
| JP2017516786A5 (enExample) | ||
| AR091605A1 (es) | Proteinas de union anti-mesotelina | |
| WO2013064700A3 (en) | Chimeric human-camel antigens and their use | |
| NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
| WO2021203030A3 (en) | Methods of use of anti-trem2 antibodies | |
| NZ785401A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| EP4276108A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |